September 11, 2025 4:50pm

… Of market risk and share pricing has revolved around econs as traders upped the ante, today

Remember, “The sector is what it is, until it isn’t, even if it doesn’t seem to be, it yet will be.” 

Never leave an investor uninformed!  

I answer or qualify the sector’s equity’s movement; with an emphasis on which company is gaining or losing stride in your portfolio for the short-term

A question … will a “sticky” inflation report kick the Fed to cook a 25-basis point interest rate cut next week, but it is NOT likely to make a 50-basis cut. As needed, expectation will be what is easier and which versus needed?

 

Thursday’s RegMed Investors’ (RMi) pre-open: CPI headwinds and jobless headlights https://www.regmedinvestors.com/articles/14101

RegMed Investors (RMi) Research Note: Harvard Apparatus GT (OTCQB): Just another wrinkle – Q2/25’s 10-Q – liabilities exceed cash position … https://www.regmedinvestors.com/articles/13812

 

Thursday: The Dow closed UP +617.08 points or +1.36%, the S&P closed UP +55.43 points or +0.85% while the Nasdaq closed UP +157.014 points or +0.72%

  • Theme of the session, the latest reading of a key consumer inflation gauge

Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy

  • The CPI reading showed an increase of 0.4% for the month, higher than the 0.3% that economists were expecting. However, the index recorded 2.9% on a 12-month basis, as expected; the core CPI, which excludes volatile food and energy, increased 0.3% in August and 3.1% from a year ago.

Thursday’s my 40-company covered sector’s advance/decline line opened positive with 27 incliners, 12 decliners and 1 flat ending with a positive close of 27 incliners, 11 decliners and 2 flats

Metrics:  Thursday, the IBB was up +3.15%, the XBI was up +1.80% while the VIX was down -0.66 points or -4.30% at 14.69

 

Q3 – 1 holiday, 3 negative and 5 positive closes

  • August – 12 negative and 9 positive closes
  • July – 1 market holiday, 13 positive and 9 negative closes

 

Thursday Closing UP (10 of 27) 

  • Vertex Pharmaceuticals (VRTX +$8.82 after Wednesday’s -$7.93, Tuesday’s +$1.23 and Monday’s -$0.87),
  • IQV Holdings (IQV +$6.77 after Wednesday’s -$5.77 and Tuesday’s +$1.99),
  • CRISPR Therapeutics (CRSP +$4.08 after Wednesday’s -$1.88),
  • BioNTech SE (BNTX +$3.31 after Wednesday’s -$1.09, Tuesday’s -$0.57 and Monday’s -$9.80),
  • Vericel (VCEL +$2.22 after Wednesday’s -$1.23, Tuesday’s -$0.68 and Monday’s -$0.83),
  • Beam Therapeutics (BEAM +$1.67 after Wednesday’s -$0.49, Tuesday’s +$0.42 and Monday’s -$0.94),
  • Moderna (MRNA +$1.08),
  • Arrowhead Pharmaceuticals (ARWR +$0.83 after Wednesday’s +$1.16, Tuesday’s +$0.56 and Monday’s -$1.91),
  • AxoGen (AXGN +$0.73),
  • Sarepta Therapeutics (SRPT +$0.69 and Wednesday’s -$0.42),

Flat (2)

  • Harvard Apparatus RT (OTCQB: HRGN $0.00 after Wednesday $0.00, Tuesday's $0.00 and Monday’s +$0.17)
  • Sangamo Therapeutics (SGMO)

Thursday’s Closing DOWN (11 of 11): 

  • Lenz Therapeutics (LENZ -$0.90 after Wednesday’s +$1.82),
  • Alnylam Pharmaceuticals (ALNY -$0.73 after Wednesday’s -$12.82, Tuesday’s +$27.10 and Monday’s +$3.03),
  • uniQure NV (QURE -$0.54),
  • Wave Life Sciences (WVE -$0.23),
  • Mesoblast (MESO -$0.19 after Wednesday’s +$0.56, Tuesday’s +$0.45 and Monday’s +$0.16),
  • Adverum Biotechnologies (ADVM -$0.17)
  • Agenus (AGEN -$0.09),
  • Regenxbio (RGNX -$0.08),
  • Cellectis SA (CLLS -$0.07 after Wednesday’s +$0.20),
  • Ultragenyx Pharmaceuticals (RARE -$0.06)
  • Brainstorm Cell Therapeutics (BCLI -$0.0265),

 

The BOTTOM LINE:  More of the … WHYs …

All three of the US market indexes (^DJI, ^IXIC, ^GSPC) closed Thursday's session at record highs …

  • Cell and gene therapy equities rose on Thursday as traders recognized that the latest reading of a key consumer inflation gauge won’t stand in the way of the Fed “aka” Jerome lowering its benchmark interest rate next week.

From CNBC, “With growing evidence of softening U.S. economic growth, markets are pricing in a quarter percentage point at the conclusion of Fed’s Sept. 17 meeting with near certainty, according to the CME FedWatch tool. Odds that the central bank will cut by a half percentage point have also ticked higher.”

  • A ¼-point cut is a layup and the number still keeps a half-point cut on the table, especially when looking at the jobless data. The bottom line is watching the 10-year Treasury yield. If a 3-handle on the 10-year, materializes the market could rally here.

Reiterating from Monday, “The cell and gene therapy are riding the skids of “uncle algo and his electronic trading dwarfs” skid while currently residing and staying in a … catalyst vacuum with more downside drift potentially coming into the markets which is … flirting with all-time highs in a … seasonally weak period.”

  • Again, Friday’s consumer sentiment could offer uncertain mix of upcoming inflation pressures
  • However, today’s market received yet another sign that it’s slowing, as weekly jobless claims saw a surprise jump after job growth figures were revised down earlier this week

… unless there’s some event out of left field with regard to tariffs or who knows what …

 

September: understand the “flow” …

  • 9/11 - Thursday closed positive with 27 positive, 11 negative and 2 flats
  • 9/10 – Wednesday closed negative with 13 positive, 26 negative and 1 flat
  • 9/9 - Tuesday closed positive with 24 positive, 15 negative and 1 flat
  • 9/8 – Monday closed negative with 10 positive, 28 negative and 2 flats
  • 9/5 - Friday closed positive with 35 positive, 5 negative and 0 flat
  • 9/4 – Thursday closed negative with 17 positive, 21 negative and 2 flats
  • 9/3 - Wednesday closed positive with 22 positive, 16 negative and 2 flats
  • 9/2 -Tuesday closed positive with 22 positive, 18 negative and 0 flat
  • 9/1 -Monday was a holiday

Welcome to my world of defining the “grey’ in our universe!

  • “I hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”
  • If I have learned one thing as a former research analyst in a venture and public fund, operating executive, x-FBI, x-military officer and an adjunct (MBA) business school professor now a journalist; my life and your portfolio are largely tied to knowledge of price movements and questioning pricing targets and more.
  • I was once told by a “very” prominent figure early in my career, “write it right, keep it tight without hype and never lose the stride to guide the reader” – they were pretty simple instructions to follow!

 

Why do I keep repeating, so investors can make the connection …

The top three (3) performing in the session:   

  • Thursday: Vertex (VRTX), IQV Holdings (IQV) and CRISPR Therapeutics (CRSP)
  • Wednesday: Lenz Therapeutics (LENZ), Arrowhead Pharmaceuticals (ARWR) and Mesoblast (MESO)
  • Tuesday: Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS) and IQV Holdings (IQV)
  • Monday: Alnylam Pharmaceuticals (ALNY), Prime Medicine (PRME) and Harvard Apparatus RT (OTCQB: HRGN)

The worst three (3) in the session: 

  • Thursday: Alnylam Pharmaceuticals (ALNY), Lenz Therapeutics (LENZ) and uniQure NV (QURE)
  • Wednesday: Alnylam Pharmaceuticals (ALNY), Vertex (VRTX) and IQVIA Holdings (IQV)
  • Tuesday: Vericel (VCEL), BioNTech (BNTX) and CRISPR Therapeutics (CRSP)
  • Monday: BioNTech (BNTX), Lenz Therapeutics (LENZ) and Arrowhead Pharmaceuticals (ARWR)

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.